TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+2.9%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.56B
AUM Growth
+$2.56B
(-2.7%)
Cap. Flow
-$98.6M
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
40.31%
Holding
186
New
9
Increased
28
Reduced
31
Closed
20
Top Buys
| 1 |
Merck
MRK
|
$20.3M |
| 2 |
Amgen
AMGN
|
$13.5M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$13.2M |
| 4 |
Insulet
PODD
|
$12.6M |
| 5 |
Tenet Healthcare
THC
|
$12.1M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$35.4M |
| 2 |
Cigna
CI
|
$24.2M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$21.6M |
| 4 |
Bristol-Myers Squibb
BMY
|
$13.1M |
| 5 |
UnitedHealth
UNH
|
$13.1M |
Sector Composition
| 1 | Healthcare | 96.11% |
| 2 | Real Estate | 2.09% |
| 3 | Industrials | 0.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Cigna
CI
$80.4B
| $27M | 1.06% |
96,339
-86,292
| -47% | -$24.2M |
|
27
McKesson
MCK
$86.1B
| $26.5M | 1.04% |
61,955
-4,500
| -7% | -$1.92M |
|
28
argenx
ARGX
$42.8B
| $25.5M | 1% |
65,553
-22,757
| -26% | -$8.87M |
|
29
HCA Healthcare
HCA
$94.9B
| $25M | 0.98% |
82,403
-6,300
| -7% | -$1.91M |
|
30
Stryker
SYK
$149B
| $24.8M | 0.97% |
81,128
+9,550
| +13% | +$2.91M |
|
31
IQVIA
IQV
$31.3B
| $24.5M | 0.96% |
109,129
+46,012
| +73% | +$10.3M |
|
32
Zoetis
ZTS
$67.4B
| $23.6M | 0.92% |
136,914
| – | – |
|
33
Charles River Laboratories
CRL
$7.9B
| $23.4M | 0.91% |
111,183
-6,900
| -6% | -$1.45M |
|
|
SGEN
34
DELISTED
Seagen Inc. Common Stock
SGEN
| $21.6M | 0.85% |
112,331
-112,332
| -50% | -$21.6M |
|
35
Sarepta Therapeutics
SRPT
$1.83B
| $20.5M | 0.8% |
179,437
-106,216
| -37% | -$12.2M |
|
36
Novo Nordisk
NVO
$249B
| $19.9M | 0.78% |
122,777
+11,454
| +10% | +$1.85M |
|
37
Molina Healthcare
MOH
$9.94B
| $18.6M | 0.73% |
61,856
| – | – |
|
38
Jazz Pharmaceuticals
JAZZ
$7.9B
| $18.3M | 0.72% |
147,779
| – | – |
|
39
BioMarin Pharmaceuticals
BMRN
$11.3B
| $18.3M | 0.72% |
210,789
-89,300
| -30% | -$7.74M |
|
40
Edwards Lifesciences
EW
$47.9B
| $17.9M | 0.7% |
189,597
+18,451
| +11% | +$1.74M |
|
41
Humana
HUM
$37.3B
| $16.5M | 0.64% |
36,794
| – | – |
|
42
Apellis Pharmaceuticals
APLS
$3.58B
| $15.8M | 0.62% |
173,248
+38,124
| +28% | +$3.47M |
|
43
Baxter International
BAX
$12.4B
| $14.8M | 0.58% |
324,370
+257,058
| +382% | +$11.7M |
|
44
Exelixis
EXEL
$9.86B
| $13.9M | 0.54% |
726,639
| – | – |
|
45
Novartis
NVS
$244B
| $13.7M | 0.54% |
136,225
| – | – |
|
|
KRTX
46
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $12.7M | 0.5% |
58,577
+5,125
| +10% | +$1.11M |
|
|
47
Insulet
PODD
$24.2B
| $12.6M | 0.49% |
+43,847
| New | +$12.6M |
|
48
Guardant Health
GH
$8.35B
| $12.4M | 0.48% |
346,084
-126,100
| -27% | -$4.51M |
|
49
Ascendis Pharma
ASND
$12.2B
| $12.4M | 0.48% |
138,791
+15,000
| +12% | +$1.34M |
|
50
SPDR S&P Biotech ETF
XBI
$5.24B
| $12.3M | 0.48% |
147,677
| – | – |
|